[图书][B] Access to high-priced medicines in lower-income countries in the WHO European Region
Lower-income countries ( LICs) in the WHO European Region generally have poorer health
status and more limited resources than higher-income countries. This creates pressing …
status and more limited resources than higher-income countries. This creates pressing …
The transferability of health technology assessment: the European perspective with focus on central and Eastern European countries
ABSTRACT Introduction Lower-income European countries have a worse health status and
less funds for health care compared to Western Europe. Despite their limited human and …
less funds for health care compared to Western Europe. Despite their limited human and …
Assessing the consequences of external reference pricing for global access to medicines and innovation: economic analysis and policy implications
Background: External reference pricing (ERP) is used to set pharmaceutical prices to
improve affordability, but its application may have negative consequences on patient access …
improve affordability, but its application may have negative consequences on patient access …
Application of managed entry agreements for innovative therapies in different settings and combinations: a feasibility analysis
RA Vreman, TF Broekhoff, H GM Leufkens… - International Journal of …, 2020 - mdpi.com
The reimbursement of expensive, innovative therapies poses a challenge to healthcare
systems. This study investigated the feasibility of managed entry agreements (MEAs) for …
systems. This study investigated the feasibility of managed entry agreements (MEAs) for …
Talkin'about a resolution: issues in the push for greater transparency of medicine prices
B Shaw, J Mestre-Ferrandiz - Pharmacoeconomics, 2020 - Springer
Abstract At the 2019 World Health Assembly, a significant new resolution was agreed by
most countries to start publicly sharing information on the real net prices they pay for …
most countries to start publicly sharing information on the real net prices they pay for …
Speculation, climate or pandemic: Who drives the Chinese herbal medicine bubbles?
Reducing excessive price fluctuations of Chinese herbal medicines is crucial to the high-
quality development of traditional Chinese medicine. The research utilises the relatively …
quality development of traditional Chinese medicine. The research utilises the relatively …
Impact of changes in the methodology of external price referencing on medicine prices: discrete-event simulation
S Vogler, P Schneider, L Lepuschütz - Cost Effectiveness and Resource …, 2020 - Springer
Background Several governments apply the policy of external price referencing (EPR),
which considers the prices of a medicine in one or more other countries for the purpose of …
which considers the prices of a medicine in one or more other countries for the purpose of …
A new pricing mechanism for pharmaceutical supply chains: a game theory analytical approach for healthcare service
Health care accounts for a substantial amount of government spending and is one of the
most vulnerable sectors of theeconomy. Having a significant role to play in saving lives …
most vulnerable sectors of theeconomy. Having a significant role to play in saving lives …
How does external reference pricing work in developing countries: evidence from Iran
F Babaie, MH Motevalli, G Mehralian… - Frontiers in …, 2023 - frontiersin.org
Introduction: Governments apply different pricing policies to ensure public accessibility,
availability, and affordability of medicines. In this way, external reference pricing (ERP) …
availability, and affordability of medicines. In this way, external reference pricing (ERP) …
Current and future perspectives for the implementation of health technology assessment in Romania
Abstract Health Technology Assessment (HTA) is a complex approach increasingly used
worldwide to make transparent and evidence-based reimbursement decisions for health …
worldwide to make transparent and evidence-based reimbursement decisions for health …